In World First, Baby Receives Personalized CRISPR Gene-Editing Treatment<\/p>\n
A CRISPR treatment seems to have been effective for a baby\u2019s devastating disease, but it is not clear whether such bespoke therapies can be widely applied<\/p>\n<\/div>\n
By Heidi Ledford<\/a> & Nature magazine<\/a> <\/p>\n KJ Muldoon, a baby born with a genetic disease that affected his ability to metabolize proteins, has become the first person to receive a bespoke CRISPR treatment.<\/p>\n<\/div>\n Children’s Hospital of Philadelphia<\/p>\n<\/div>\n<\/figcaption><\/figure>\n<\/div>\n A baby boy with a devastating genetic disease is thriving after becoming the first known person to receive a bespoke, CRISPR therapy<\/a>-for-one, designed to correct his specific disease-causing mutation.<\/p>\n Little KJ Muldoon, now nearly ten months old, is doing well after receiving three doses of a gene-editing treatment<\/a> to mend a mutation that impaired his body\u2019s ability to process protein, his parents told reporters this week. But it is too soon to use the word \u201ccure\u201d, says Rebecca Ahrens-Nicklas, a pediatrician at Children\u2019s Hospital of Philadelphia in Pennsylvania, and one of Muldoon\u2019s physicians. \u201cThis is still really early days,\u201d she says. \u201cWe know we have more to learn from him.\u201d<\/p>\n To reach this point, an international team of clinicians and researchers in industry and academia, with support from US government funders and regulatory agencies, raced to develop Muldoon\u2019s therapy in a mere six months. Yet, the drug that it developed, described in the New England Journal of Medicine<\/i><\/a> <\/i>on May 15, is specific to Muldoon\u2019s genetic sequence and will probably never be used for another person, says Ahrens-Nicklas.<\/p>\n If you’re enjoying this article, consider supporting our award-winning journalism by subscribing<\/a>. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.<\/p>\n It\u2019s an ambitious approach that researchers hope will inspire others to harness CRISPR to treat ultra-rare genetic diseases. \u201cThis truly is the future for all of these gene and cell therapies,\u201d says Arkasubhra Ghosh, who studies gene therapy<\/a> at Narayana Nethralaya Eye Hospital in Bengaluru, India, and who was not involved in the study. \u201cIt\u2019s really exciting.\u201d<\/p>\n Dozens of people have received CRISPR-based therapies for genetic conditions such as sickle-cell anaemia<\/a>, but those treatments were designed to be used in many people with the same disorder, regardless of the underlying mutations that caused it. By contrast, researchers tailored Muldoon\u2019s therapy to correct a specific genetic sequence in his genome.<\/p>\n Muldoon had inherited two mutations, one from each parent, that meant that he did not produce the normal form of a crucial enzyme called carbamoyl phosphate synthetase 1 (CPS-1). This compromised his ability to process the nitrogen-containing compounds produced when the body breaks down protein. As a result, his blood had high levels of ammonia, a compound that is particularly toxic to the brain.<\/p>\n The best treatment for CPS-1 deficiency is a liver transplant<\/a>, but it would be months before Muldoon became eligible. Meanwhile, each day brought added risk of brain damage or death: only about half of babies with severe CPS-1 deficiency survive long enough to receive a transplant.<\/p>\n Ahrens-Nicklas decided to offer the family another option. She and her colleagues had been working with a CRISPR-based technique called base editing<\/a>, which can make targeted, single-letter changes to DNA sequences. The team was developing ways to quickly and safely tailor a base-editing therapy to correct an individual\u2019s particular mutations. Perhaps now it was time to try the approach in humans, she thought.<\/p>\n With the approval of Muldoon\u2019s parents, the researchers enlisted a lengthy roster of collaborators. The team quickly screened for the best base-editing approach and tested it in mice and monkeys. Companies donated proprietary expertise and components. The US Food and Drug Administration fast-tracked its evaluation of the treatment.<\/p>\n In just six months, Muldoon received his first dose \u2014 a \u201cremarkable\u201d achievement, says Waseem Qasim, a pediatrician at the University College London Great Ormond Street Institute of Child Health, who has used base editing to engineer immune cells to fight cancer.<\/p>\n After that initial dose, Muldoon could safely eat the amount of protein recommended for his age, but still needed medications to keep his ammonia levels in check. With a second round of the therapy, the researchers were able to reduce the amount of medicines needed, but could not eliminate his need to take them.<\/p>\n Muldoon has since received a third and final dose. His clinicians are carefully reducing his medication dosage, little by little, says Ahrens-Niklas.<\/p>\n It\u2019s unclear how this approach could be expanded to treat others with ultra-rare diseases: even when designed to treat hundreds of people, gene therapies and gene-editing therapies are notoriously expensive. \u201cThere\u2019s no great answer to this,\u201d says Qasim.<\/p>\n For now, each milestone that Muldoon reaches is a tiny miracle to his parents. Earlier this week, his mother, Nicole, walked into his hospital room to find him sitting up by himself in his crib. \u201cWe never thought this was going to happen,\u201d she says.<\/p>\n This article is reproduced with permission and was <\/i>first published<\/i><\/a> on May 15, 2025<\/i>.<\/p>\n<\/div>\n![\"Drs.](\"https:\/\/static.scientificamerican.com\/dam\/m\/769188b66180f6e7\/original\/drs_musunuru_and_ahrens_nicklas_holding_kj.jpg?m=1747414286.613&w=600\")
On supporting science journalism<\/h2>\n
Early illness<\/h2>\n
Rapid deployment<\/h2>\n